METHOD FOR TREATING CANCER USING ARTIFICIAL ADJUVANT CELL (aAVC)

Abstract

Provided is an effective and safe method for treating or preventing a cancer using aAVC. The present invention finds suitable ranges of the dose of α-GalCer loaded on aAVC cell surface, and the amount of α-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.

1 .- 5 . (canceled) 
     
     
         6 . A pharmaceutical composition for treating or preventing a cancer, comprising a human-derived cell,
 wherein the cell expresses exogenous CD1d and has α-GalCer loaded on the cell surface, and wherein the composition is administered to a human such that a single dose of α-GalCer loaded on the cell surface is 1.7 ng to 275 ng per kg body weight of the human.   
     
     
         7 . The pharmaceutical composition according to  claim 6 , wherein the human-derived cell expresses an exogenous cancer antigen. 
     
     
         8 . The pharmaceutical composition according to  claim 6 , wherein the CD1d is human CD1d. 
     
     
         9 . The pharmaceutical composition according to  claim 6 , wherein the human-derived cell is a human embryonic kidney cell 293 (HEK293)-derived cell. 
     
     
         10 . The pharmaceutical composition according to  claim 6 , wherein the amount of α-GalCer loaded on the cell surface is in the range of 3.9 to 275 ng per 1×10 6  cells. 
     
     
         11 .- 20 . (canceled) 
     
     
         21 . A method for producing a human-derived cell that expresses exogenous CD1d and has α-GalCer loaded on the cell surface, wherein the cell is administered to a human such that a single dose of α-GalCer loaded on the cell surface ranges from 1.7 ng to 275 ng per kg body weight of the human, and wherein the method comprises culturing human-derived cells expressing exogenous CD1d in a culture medium containing 56 ng/mL to 3000 ng/mL α-GalCer. 
     
     
         22 . The method according to  claim 21 , further comprising measuring the amount of α-GalCer loaded on the cells obtained by the culture step, and selecting a cell wherein the amount of α-GalCer loaded on the cell surface is in the range of 3.9 to 275 ng per 1×10 6  cells.